Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

in 2009.  For the three and nine months ended September 30, 2010, net loss included non-cash, stock-based compensation expense of $1.3 million and $4.0 million, respectively.  For the three and nine months ended September 30, 2009, net loss included non-cash, stock-based compensation expense of $1.3 million and $4.1 million, respectively.  

Cash and Investments:  As of September 30, 2010, Lexicon had $231.0 million in cash and investments, as compared to cash and investments, net of its obligations under the credit line secured by its auction rate securities, of $255.8 million as of June 30, 2010 and $125.1 million as of December 31, 2009.  On June 30, 2010, Lexicon exercised its rights to require UBS AG to purchase its remaining auction rate securities, and UBS purchased the auction rate securities at par value on July 1, 2010.

Lexicon Conference Call:Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the third quarter of 2010 at 11:00 a.m. Eastern Time on November 5, 2010.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20791091.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through November 12, 2010.

About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery ef
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky One ... a,leading fully integrated pharmaceutical company producing over-the-counter,drugs in the ... for the fourth quarter and fiscal year ended December ... Highlights, -- Total revenues increased 104.0% ...
... pleased to announce,that its licensee Daiichi Sankyo (Tokyo, ... TwinCaps(R) dry powder inhaler device in the launch ... active,against the influenza virus. Daiichi Sankyo has completed ... and other Asian countries and results,are expected to ...
... to Focus on Drug Development for Neurological ConditionsBROOMFIELD, ... company delivering breakthrough therapies in central nervous system ... Pharmaceuticals, Inc., a drug development company. The ... development of proprietary small molecule drugs for acute ...
Cached Biology Technology:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 2China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 4China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 5China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 6China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 7China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 8China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 9China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 10Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza 2Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza 3Accera, Inc. Launches Neuera Pharmaceuticals, Inc. 2Accera, Inc. Launches Neuera Pharmaceuticals, Inc. 3
(Date:4/17/2014)... Researchers reporting in the Cell Press journal Current ... insects with rather novel sex lives. The Brazilian insects, ... genus Neotrogla , are the first example of ... reversal has been identified in several different animals, ... intromittent organ is also reversed," says Kazunori Yoshizawa from ...
(Date:4/17/2014)... of Texas Medical Branch at Galveston are the ... radiation for cervical cancer should begin colorectal cancer ... UTMB researchers, finding a high incidence of secondary ... radiation, offer new recommendations that the younger women ... eight years after their initial cervical cancer diagnosis ...
(Date:4/17/2014)... National University (ANU), have developed a new way ... over the past 5.3 million years., The findings ... ice ages over the past two million years, ... dioxide levels, global temperatures and sea levels., The ... and the National Oceanography Centre (NOC) in the ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Ancient sea-levels give new clues on ice ages 2
... discovered a bone from a pterosaur (giant flying reptile or ... Velociraptor (small predatory theropod dinosaur) that lived in ... The findings published online in Palaeogeography, Palaeoclimatology, and ... carnivore with a specialised sickle shaped slashing talon on the ...
... new research discovery by a team of Stanford and European ... day be able to avoid limb amputation related to ischemia. ... FASEB Journal suggests that the delivery of genes ... and "VEGF" may successfully cause the body to grow new ...
... why immune cells, called T-cells, attack the body is ... University of Alberta researcher Troy Baldwin is a step ... healthy cells causing autoimmune diseases. , Baldwin and ... Bim, which is vital in regulating T-cell death. When ...
Cached Biology News:Dinosaur fossil: Even specialized predators didn't turn down free meals 2Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs 2U of Alberta researcher steps closer to understand autoimmune diseases 2
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... amino acid synthetic peptide whose sequence is from rat SCAMP 5. ... C - N(217) - Q - P - Q - ... - P - N - Y - T - Y - ... neutralization and control experiments with the polyclonal antibody that reacts with ...
... (gram quantities of IgY) , After we receive ... we segregate the appropriate number of chickens and ... eggs are collected (usually over a period of ... involves a total of four injections into the ...
Biology Products: